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We previously reported association of SCARB1 SNP rs10846744 with common carotid IMT
(cIMT) and cardiovascular disease (CVD) events. Since rs10846744 has been reported in
association with Lp-PLA2 mass and activity, we hypothesized that inflammatory pathways
might mediate the association of rs10846744 with atherosclerosis.
Methods
We first examined association of rs10846744 in CVD in multiple large-scale consortium-
based genome-wide association studies. We further examined 27 parameters of interest,
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including Lp-PLA2 mass and activity, inflammatory markers, and plasma phospholipid fatty
acids, and fatty acid ratios in participants from the Multi-Ethnic Study of Atherosclerosis
(MESA), as potential mediators in the pathway linking rs10846744 with cIMT and incident
CVD. Finally, we examined the association of rs10846744 with Lp-PLA2 activity, cardiovas-
cular outcomes, and interaction with the Lp-PLA2 inhibitor, darapladib, in the Stabilization of
Atherosclerotic Plaque by Initiation of Darapladib Therapy (STABILITY) and Stabilization of
Plaque using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52)
studies.
Results
SCARB1 rs10846744 was associated with coronary artery disease events in CARDIo-
GRAMplusC4D (odds ratio 1.05; 95% CI [1.02, 1.07]; P = 1.4x10-4). In combined analysis
across race/ethnic groups in MESA, rs10846744 was associated with Lp-PLA2 mass (P =
0.04) and activity (P = 0.001), homocysteine (P = 0.03), LDL particle number (P = 0.01),
docosahexaenoic acid [DHA] (P = 0.01), docosapentaenoic acid [DPA] (P = 0.04), DPA/
eicosapentaenoic acid [EPA] ratio (P = 0.002), and DHA/EPA ratio (P = 0.008). Lp-PLA2
activity was identified as a mediator of rs10846744 with cIMT in a basic model (P = 8x10-5),
but not after adjustment for CVD risk factors. There was no interaction or modifier effect of
the Lp-PLA2 inhibitor darapladib assignment on the relationship between rs10846744 and
major CVD events in either STABILITY or SOLID-TIMI 52.
Summary
SCARB1 rs10846744 is significantly associated with Lp-PLA2 activity, atherosclerosis, and
CVD events, but Lp-PLA2 activity is not a mediator in the association of rs10846744 with
cIMT in MESA.
Introduction
In this era of genome wide association studies (GWAS), there is a need to identify the causal
pathways of significant single nucleotide polymorphisms (SNP) on disease phenotypes. We
showed that the scavenger receptor class B type I gene (SCARB1) intronic rs10846744 SNP was
significantly associated with subclinical atherosclerosis (SCA) as measured by common carotid
intima-media thickness (cIMT) in participants from the Multi-Ethnic Study of Atherosclerosis
(MESA) [1]. In the full MESA cohort and in replication studies, we showed that rs10846744
was significantly associated with SCA and cardiovascular disease (CVD) events [2]. The associ-
ation of rs10846744 with SCA and CVD events remained significant after multivariable regres-
sion analysis that included total, LDL and HDL cholesterol and particle sizes, age, sex, race,
body mass index (BMI), hypertension, smoking, diabetes mellitus, renal disease, and lipid low-
ering medications. Thus, we hypothesized that factors other than lipids and other traditional
cardiovascular risk factors might mediate the relationship between SCARB1 SNP rs10846744
and risk of atherosclerotic disease.
Suchindran et al. [3] had performed a GWAS of lipoprotein-associated phospholipase A2
(Lp-PLA2) mass and activity in participants from the Framingham Heart Study, and identified
rs10846744 as being positively associated with Lp-PLA2 mass and activity. Grallert et al. [4]
reported that rs10846744 was positively associated with Lp-PLA2 activity but not Lp-PLA2
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mass in an expanded GWAS from the CHARGE consortium. In agreement to what we
observed, Kleber et al. [5] showed that Lp-PLA2 mass predicted total and cardiovascular mor-
tality independently of known CV risk factors. These results led us to the refined hypothesis
that an inflammatory and/or fatty-acid related pathway might be causal in the association of
rs10846744 with atherosclerotic disease.
In this study we sought to (i) validate the association of rs10846744 with SCA and CV
events from consortium-based GWAS, (ii) examine associations of rs10846744 with Lp-PLA2
mass and activity, inflammatory markers and fatty acids in MESA, and (iii) perform formal
mediation analyses to quantify the role of selected covariates as mediators of the association of
rs10846744 with cIMT in MESA. We expanded our analyses to examine the association
between rs10846744 and Lp-PLA2 activity and CV events from the STABILITY and SOLID--
TIMI 52 trials, in addition to the interaction with the Lp-PLA2 inhibitor darapladib [6,7].
Methods
We present an overview of our approach in Fig 1. Detailed Methods are provided below.
SCA and CAD from GWAS cohorts
We examined the association of rs10846744 with SCA in a GWAS of cIMT, internal carotid
IMT [iIMT] and plaque in cohorts of European ancestry from the CHARGE consortium [8].
We examined the association of rs10846744 with coronary heart disease (CHD) in results
from the GWAS of African-American cohorts in CARe [9] and with coronary artery disease
(CAD) in cohorts of various ancestries from the CARDIoGRAMplusC4D consortium [10].
CHARGE: GWAS analyses on IMT were performed by meta-analysis of ~31,000 individuals
from nine participating studies within Cohorts for Heart and Aging Research in Genomic Epi-
demiology (CHARGE) [11]. CARe: African-American participants for the GWAS were drawn
from five population-based studies: Atherosclerosis Risk in Communities, Coronary Artery
Risk Development in young Adults, Cleveland Family Study, Jackson Heart Study, and MESA
[9]. Genetic analysis of CHD in CARe included 881 cases and 6682 controls CARDIoGRAM-
plusC4D: The Coronary ARtery DIsease Genome-wide Replication And Meta-Analysis (CAR-
DIoGRAM) plus The Coronary Artery Disease (C4D) Genetics) consortium combined data
from GWAS on>60,000 CAD cases and >123,000 controls representing primarily European
ancestry (77% of participants), with other race/ethnic groups represented [10].
MESA study design
MESA is a longitudinal study of SCA and risk factors that predict progression to clinically
overt CVD or progression of the subclinical disease [12]. The first clinic visits occurred in
2000–2002 in 6,814 participants recruited from six field centers across the United States, and
all participants were free of CVD at the baseline exam. Approximately 38% of the recruited
participants were Caucasian, 28% African-American, 22% Hispanic, and 12% Asian, predomi-
nantly of Chinese descent, with race/ethnicity classified based on participant self-report
(Table 1). One ancillary study (MESA Family Study, MESAFS) recruited family members of
African-American and Hispanic participants, specifically for genetic studies. Another ancillary
study (MESA Air) evaluated the effects of air pollution on atherosclerosis risk [13].
Phenotyping of MESA participants
SCA and CV. The measures of SCA included ultrasound measurements of cIMT and
iIMT [14]. Cardiovascular events were adjudicated by a MESA committee [15]. CV events
Lp-PLA2, SCARB1 and CVD
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included incident myocardial infarction (MI), definite angina, probable angina (if followed by
coronary artery bypass grafting and percutaneous coronary intervention), resuscitated cardiac
arrest, stroke, stroke death, coronary heart disease death, or other CV death. We examined
probable or confirmed CV events described as CV-All, confirmed CV events described as
CV-Hard, incident MI, and all-cause mortality.
Lp-PLA2 mass and activity. Lp-PLA2 mass and activity were measured by diaDexus Inc.
(South San Francisco, CA, USA) [16].
Inflammatory markers. Six inflammatory markers were selected for the association stud-
ies: interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), plasminogen activator
inhibitor-1 (PAI-1), soluble intercellular adhesion molecule-1 (sICAM-1), E-selectin, and
homocysteine. Blood samples were collected at baseline and stored at –80˚C until analysis.
Interleukin-6, hsCRP, and PAI-1 levels were measured at the Laboratory for Clinical Biochem-
istry Research (University of Vermont, Burlington, VT) while homocysteine was measured at
the University of Minnesota. The samples were processed using a standardized protocol from
the Cardiovascular Health Study (CHS) [17]. Plasma IL-6, sICAM-1, and E-selectin were
Fig 1. Overview of approach.
https://doi.org/10.1371/journal.pone.0204352.g001
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Table 1. Characteristics of MESA, MESA family and MESA Air participants across four ethnic groups.
Participant characteristics Caucasian African-
American
Hispanic Chinese-American
No. subjects n = 2470 n = 2507 n = 2071 n = 758

























Education: completed technical degree, associate degree, bachelor’s degree or higher 1492 (60.6) 1229 (49.3) 438 (21.1) 390 (50.5)












































































Clinical events n = 2467 n = 1602 n = 1426 n = 758
CV-All (yes/no) 313 (12.7) 177 (11.0) 173 (12.1) 64 (8.4)
CV-Hard (yes/no) 210 (8.5) 131 (8.2) 136 (9.5) 39 (5.1)
Death (all-cause) (yes/no) 369 (15.0) 274 (17.1) 186 (13.0) 76 (10.0)
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measured using quantitative enzyme-linked immunosorbent assays (Quantikine HS Human
IL-6 Immunoassay, Parameter Human sICAM-1 Immunoassay, Parameter Human sE-Selec-
tin Immunoassay, respectively; R&D Systems, Minneapolis, MN). PAI-1 levels were measured
by ELISA (Diagnostica Stago, Inc., Parsippany, NJ). Plasma homocysteine levels were mea-
sured using a fluorescence polarization immunoassay (IMx homocysteine assay, Axis Bio-
chemicals ASA, Oslo, Norway) with the IMx analyzer (Abbott Diagnostics, Abbott Park, IL).
Fatty acids: Phospholipid fatty acids were extracted from EDTA plasma [18,19]. Lipids were
extracted from the plasma using a chloroform/methanol extraction method, and the choles-
terol esters, triglyceride, phospholipids and free fatty acid fractions were separated by thin
layer chromatography. Fatty acids from the phospholipid fractions were derivatized to methyl
esters and then injected on a gas chromatograph equipped with a 100m capillary column, and
detected by flame ionization. The fatty acids detected were expressed as a percent of total fatty
acids.
Table 1. (Continued)
































































































































SCARB1 rs10846744 frequency of effect allele C (vs. reference allele G) 0.18 0.62 0.35 0.57
Data are presented as n (%) for binary measures or median [IQR] for continuous measure.
Clinical events are reported for MESA Classic participants only and reflect a smaller sample size compared to other measures. CV-All includes suspected and
adjudicated cases; CV-Hard includes only adjudicated cases.
https://doi.org/10.1371/journal.pone.0204352.t001
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Genotyping. All MESA participants were genotyped on the Affymetrix 6.0 array which
included the rs10846744 SNP. Details are provided in S1 File.
Statistical analysis in MESA
We examined the association of rs10846744 with Lp-PLA2 mass and activity, hsCRP, homo-
cysteine, IL-6, E-selectin, PAI-1, sICAM-1, LDL particle number, n-3 fatty acids (α-linolenic
acid [ALA], eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], docosapentaenoic
acid [DPA]) and n-6 fatty acids (linoleic acid [LA], gamma-linoleic acid [GLA], dihomo-
gamma-linoleic acid [DGLA], arachidonic acid [AA]), in addition to 10 different fatty acid
ratios (listed in Table 2). We performed linear regression of quantitative phenotypes or logistic
regression of dichotomous phenotypes in R [20]. Fixed effect meta-analysis was performed to
combine estimated effects and standard errors from stratified analyses, as implemented in
METAL [21]. We further implemented trans-ethnic meta-analysis using MANTRA [22]. We
also report Heterogeneity I-squared and Heterogeneity P-values from Cochran’s Q test as
implemented in METAL [21].
For potential mediators demonstrating a statistically significant main association with
rs10846744 in meta-analysis across race/ethnic groups (based on fixed effects meta-analysis p-
value reaching the Bonferroni threshold of α0.05/27 traits0.0019, or a trans-ethnic meta-
analysis log10 Bayes factor of association > 1.5), we proceeded to perform mediation analysis
by performing formal comparisons of regression models with and without the mediators of
interest. Details are provided in S1 File.
STABILITY and SOLID-TIMI 52 studies
We examined the association of rs10846744 with Lp-PLA2 activity, cardiovascular outcomes,
and interaction with the Lp-PLA2 inhibitor, darapladib, in the Stabilization of Atherosclerotic
Plaque by Initiation of Darapladib Therapy (STABILITY) and Stabilization of Plaque using
Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) studies.
STABILITY was a multinational double-blind trial that randomly assigned 15,828 subjects
with stable CHD to either once-daily darapladib or placebo therapy for a median follow-up
period of 3.7 years [6]. The primary endpoint for STABILITY was time to CV death, MI or
stroke. In STABILITY, multivariable regression models included adjustment for age, sex,
region, BMI, hyperlipidemia, statin use, baseline LDL, baseline HDL, eGFR, smoking, diabetes,
prior MI, principal components (PCs) of ancestry and randomized treatment arm.
The SOLID-TIMI 52 was a multinational, double-blind trial that enrolled 13,026 partici-
pants who had been hospitalized with an acute coronary syndrome in the past 30 days and ran-
domized them to once daily darapladib or placebo for a median follow-up of 2.5 years [7]. The
primary endpoint was CHD death, MI or urgent coronary revascularization. In SOLID-TIMI
52, multivariable regression models included adjustment for age, sex, region, BMI, hyperlipid-
emia, statin use, baseline LDL, baseline HDL, eGFR, smoking, diabetes, prior MI, index diag-
nosis (STEMI vs not), days from qualifying event, PCs of ancestry and randomized treatment
arm.
Both STABILITY and SOLID-TIMI 52 included participants of Caucasian, African-Ameri-
can, Asian and other race/ethnicities, as determined by participant self-report. In STABILITY
and SOLID-TIMI 52, meta-analysis used random effects models across all race/ethnic groups.
Genotype data were generated on the HumanOmniExpressExome-8 v1 array for STABILITY
and the Axiom Biobank Plus Genotyping Array with custom content array for SOLID. Geno-
type imputation was performed using the 1000 Genomes Project phase I reference panel for
Lp-PLA2, SCARB1 and CVD
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Table 2. Results of associations between rs10846744 and the mediation factors within MESA race/ethnic groups.
Mediator Group N Beta SE P-value log10 Bayes Factor Heterogeneity
I-squared /
Heterogeneity P-value
Lp-PLA2 mass, ng/ml Caucasian 1842 2.934 1.665 0.08
African-American 1155 -1.252 1.728 0.47
Hispanic 1130 3.224 1.561 0.04
Chinese-American 602 1.781 2.358 0.45
Meta-analysis 1.775 0.882 0.04 0.30 32.0 / 0.22
Lp-PLA2 activity, nmol/min/ml Caucasian 1861 1.541 1.356 0.26
African-American 1202 1.469 1.366 0.28
Hispanic 1155 3.573 1.384 0.01
Chinese-American 603 4.328 2.206 0.05
Meta-analysis 2.424 0.744 0.001 1.69 0.0 / 0.50
hsCRP, mg/L Caucasian 2452 0.009 0.042 0.84
African-American 1949 0.001 0.039 0.99
Hispanic 1739 0.055 0.039 0.17
Chinese-American 701 0.022 0.055 0.69
Meta-analysis 0.022 0.021 0.31 -0.25 0.0 / 0.78
Homocysteine, μmol/L Caucasian 2305 -0.007 0.010 0.46
African-American 1585 -0.011 0.010 0.26
Hispanic 1418 -0.014 0.010 0.19
Chinese-American 703 -0.019 0.013 0.16
Meta-analysis -0.012 0.005 0.03 0.69 0.0 / 0.90
IL-6, pg/ml Caucasian 2277 -0.010 0.025 0.68
African-American 1530 -0.005 0.025 0.85
Hispanic 1387 0.007 0.025 0.77
Chinese-American 695 0.013 0.036 0.73
Meta-analysis -0.001 0.013 0.97 -0.80 0.0 / 0.94
E-selectin, ng/ml Caucasian 551 -0.482 1.598 0.76
African-American 223 -0.679 2.406 0.78
Hispanic 270 -1.478 2.418 0.54
Chinese-American 93 -0.763 3.843 0.84
Meta-analysis -0.760 1.116 0.50 -0.40 0.0 / 0.99
PAI-1, ng/ml Caucasian 398 0.033 0.094 0.73
African-American 180 0.159 0.095 0.10
Hispanic 216 -0.046 0.085 0.59
Chinese-American 90 -0.092 0.116 0.43
Meta-analysis 0.019 0.048 0.70 -0.40 18.8 / 0.30
sICAM-1, ng/ml Caucasian 1249 5.421 3.252 0.10
African-American 452 -6.193 6.483 0.34
Hispanic 600 -3.829 4.686 0.41
Chinese-American 260 -3.125 5.187 0.55
Meta-analysis -0.371 2.230 0.87 -0.35 36.1 / 0.20
LDL particle number, nmol/L Caucasian 2311 8.388 12.148 0.49
African-American 1585 9.345 12.942 0.47
Hispanic 1418 41.361 13.901 0.003
Chinese-American 705 12.628 17.364 0.47
Meta-analysis 17.354 6.862 0.01 1.16 24.7 / 0.26
(Continued)
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Table 2. (Continued)
Mediator Group N Beta SE P-value log10 Bayes Factor Heterogeneity
I-squared /
Heterogeneity P-value
ALA, % Caucasian 2247 0.034 0.013 0.01
African-American 1525 0.008 0.013 0.56
Hispanic 1373 -0.008 0.015 0.58
Chinese-American 698 0.014 0.021 0.49
Meta-analysis 0.013 0.007 0.08 0.23 36.4 / 0.19
EPA, % Caucasian 1600 0.041 0.025 0.09
African-American 891 0.009 0.027 0.74
Hispanic 692 0.002 0.029 0.94
Chinese-American 51 -0.097 0.147 0.51
Meta-analysis 0.019 0.015 0.23 -0.14 0.0 / 0.60
DHA, % Caucasian 2247 0.088 0.045 0.05
African-American 1522 0.039 0.049 0.42
Hispanic 1369 0.051 0.042 0.23
Chinese-American 696 0.091 0.078 0.24
Meta-analysis 0.063 0.025 0.01 0.86 0.0 / 0.86
DPA. % Caucasian 2244 0.000 0.008 0.97
African-American 1521 0.018 0.008 0.03
Hispanic 1370 0.009 0.008 0.29
Chinese-American 694 0.011 0.013 0.43
Meta-analysis 0.009 0.004 0.04 0.53 0.0 / 0.47
LA, % Caucasian 2254 -0.049 0.113 0.67
African-American 1530 -0.084 0.105 0.42
Hispanic 1376 -0.129 0.121 0.29
Chinese-American 697 -0.290 0.191 0.13
Meta-analysis -0.107 0.062 0.08 0.24 0.0 / 0.74
GLA, % Caucasian 2238 0.000 0.002 0.98
African-American 1525 0.003 0.002 0.10
Hispanic 1368 0.000 0.002 0.82
Chinese-American 691 0.003 0.003 0.35
Meta-analysis 0.001 0.001 0.24 -0.35 0.0 / 0.60
DGLA, % Caucasian 2252 -0.010 0.031 0.75
African-American 1526 0.004 0.025 0.88
Hispanic 1377 0.031 0.035 0.38
Chinese-American 699 0.051 0.044 0.24
Meta-analysis 0.012 0.016 0.45 -0.46 0.0 / 0.64
AA, % Caucasian 2255 -0.041 0.089 0.64
African-American 1527 -0.071 0.089 0.43
Hispanic 1375 0.105 0.096 0.28
Chinese-American 698 -0.007 0.118 0.95
Meta-analysis -0.008 0.048 0.88 -0.50 0.0 / 0.57
AA/LA Caucasian 2246 0.000 0.006 0.10
African-American 1524 0.000 0.007 0.97
Hispanic 1369 0.012 0.007 0.06
Chinese-American 696 0.005 0.008 0.48
Meta-analysis 0.004 0.003 0.20 -0.19 0.0 / 0.55
(Continued)
Lp-PLA2, SCARB1 and CVD
PLOS ONE | https://doi.org/10.1371/journal.pone.0204352 October 5, 2018 9 / 19
Table 2. (Continued)
Mediator Group N Beta SE P-value log10 Bayes Factor Heterogeneity
I-squared /
Heterogeneity P-value
GLA/LA Caucasian 2244 0.000 0.001 0.81
African-American 1524 0.001 0.001 0.08
Hispanic 1372 0.000 0.001 0.64
Chinese-American 696 0.000 0.001 0.65
Meta-analysis 0.001 0.000 0.12 -0.54 0.0 / 0.86
DGLA/GLA Caucasian 2250 -0.011 0.016 0.51
African-American 1525 -0.025 0.015 0.09
Hispanic 1374 0.008 0.017 0.63
Chinese-American 698 0.009 0.025 0.73
Meta-analysis -0.009 0.009 0.33 -0.28 0.0 / 0.45
AA/DGLA Caucasian 2251 -0.002 0.012 0.86
African-American 1527 -0.008 0.012 0.51
Hispanic 1373 0.005 0.012 0.70
Chinese-American 697 -0.020 0.019 0.29
Meta-analysis -0.004 0.007 0.54 -1.09 0.0 / 0.70
DGLA/LA Caucasian 2248 0.000 0.002 0.94
African-American 1525 0.001 0.002 0.46
Hispanic 1371 0.002 0.002 0.35
Chinese-American 697 0.004 0.002 0.10
Meta-analysis 0.002 0.001 0.11 0.22 0.0 / 0.53
DHA/ALA Caucasian 2250 -0.010 0.018 0.58
African-American 1529 0.001 0.018 0.95
Hispanic 1375 0.025 0.021 0.23
Chinese-American 698 -0.011 0.027 0.69
Meta-analysis -0.002 0.010 0.87 -0.40 0.0 / 0.60
EPA/ALA Caucasian 2248 -0.002 0.022 0.94
African-American 1525 0.025 0.023 0.27
Hispanic 1370 0.032 0.023 0.16
Chinese-American 697 0.044 0.042 0.30
Meta-analysis 0.020 0.012 0.10 -0.54 0.0 / 0.65
DPA/EPA Caucasian 2248 -0.020 0.009 0.03
African-American 1527 -0.012 0.010 0.20
Hispanic 1376 -0.010 0.010 0.33
Chinese-American 697 -0.025 0.015 0.11
Meta-analysis -0.016 0.005 0.002 1.52 0.0 / 0.78
DHA/EPA Caucasian 2248 -0.024 0.017 0.17
African-American 1526 -0.030 0.019 0.12
Hispanic 1374 -0.022 0.022 0.31
Chinese-American 696 -0.051 0.034 0.148
Meta-analysis -0.028 0.011 0.008 1.09 0.0 / 0.90
(Continued)
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both studies using MACH/minimac. SCARB1 rs10846744 was directly genotyped in SOLID--
TIMI 52 and well imputed in STABILITY (imputation R2 = 0.95).
Human subjects approval
All of the studies for which we conducted data analyses in this manuscript, including MESA,
STABILITY, SOLID-TIMI 52, as well as those included in the consortium-based GWAS stud-
ies from CHARGE, CARe and CARDIoGRAMplusC4D were approved by their respective
institutional review boards and with written informed consent from the study participants. In
particular, our work on analysis of primary data from MESA was approved by the University
of Virginia Institutional Review Board for Health Sciences Research.
Results
Association of rs10846744 with SCA and CHD in GWAS
In CARDIoGRAMplusC4D [10], rs10846744 effect allele C (vs. reference allele G). was signifi-
cantly association with CAD (n cases = 60,801, n controls = 123,504; odds ratio 1.05; 95% CI
[1.02, 1.07]; P = 1.4x10-4). In the CHARGE GWAS of SCA in Caucasians [8], there was no
association between rs10846744 and cIMT (n = 23,442, P = 0.90), iIMT (n = 6,046, P = 0.28) or
carotid plaque (n = 17,222, P = 0.99). In the CARe GWAS of CHD in African-Americans [9],
there was no significant association of rs10846744 with CHD (n cases = 881, n controls = 6682,
P = 0.53). We did not observe a significant association of rs10846744 with cIMT in CHARGE
nor with CHD events in CARe.
MESA demographics
The MESA and MESA Family participants included 2,470 Caucasian, 2,507 African-American,
and 2,071 Hispanic and 758 Chinese-American individuals, roughly evenly distributed
between males and females (Table 1). Clinical events were assessed after a median 12.1 years
of follow-up. The prevalence of probable or confirmed CV events (CVD-All) was 12.7%,
11.0%, 12.1%, and 8.4% in Caucasians, African-Americans, Hispanics and Chinese-Ameri-
cans, respectively, while the prevalence of confirmed CVD events was 8.5%, 8.2%, 9.5% and
5.1%, respectively (Table 1). Consistent with our previous report [23], we observed consistent
directions of effect across race/ethnic groups for the association of cIMT with rs10846744,
Table 2. (Continued)
Mediator Group N Beta SE P-value log10 Bayes Factor Heterogeneity
I-squared /
Heterogeneity P-value
DHA/DPA Caucasian 2253 0.023 0.012 0.06
African-American 1526 -0.009 0.012 0.43
Hispanic 1376 0.004 0.013 0.77
Chinese-American 697 -0.001 0.015 0.92
Meta-analysis 0.004 0.006 0.52 -0.50 20.6 / 0.29
Regression models were adjusted for age, sex, study site, and PCs of ancestry. Genetic association shown for rs10846744 effect allele C (vs. reference allele G).
Meta-analysis results were obtained as follows: (a) P-values from fixed effects meta-analysis implemented in METAL [21], (b) log10 Bayes factors in favor of association
from trans-ethnic meta-analysis implemented in MANTRA [22], (c) Heterogeneity I-squared and Heterogeneity P-values from Cochran’s Q test as implemented in
METAL [21]. We have highlighted in bold fixed effects meta-analysis P-values reaching the Bonferroni threshold of α0.05/27 traits0.0019, and trans-ethnic meta-
analysis log10 Bayes factors>1.5
https://doi.org/10.1371/journal.pone.0204352.t002
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with little evidence of heterogeneity across groups (S1 Table, Heterogeneity I-squared = 0.0,
Heterogeneity P-value = 0.68). In contrast, the association of rs10846744 with cardiovascular
events showed considerable heterogeneity across groups (S1 Table, CVD-confirmed Hetero-
geneity I-squared = 81.6, Heterogeneity P-value = 0.001).
Association of rs10846744 with Lp-PLA2 mass and activity
Lp-PLA2 mass and activity were different between the race/ethnic groups, with the largest dif-
ference observed between Caucasians (median [interquartile range] for Lp-PLA2 mass, 188.1
[164.8, 213.5]; Lp-PLA2 activity, 153.0 [129.1, 179.1] nmol/min/ml) and African-Americans
(Lp-PLA2 mass 162.2 [136.5, 188.1] ng/ml; Lp-PLA2 activity, 134.4 [112.8, 158.3] nmol/min/
ml, Bonferroni corrected for all pairwise race/ethnic comparisons P = 4.9×10−67 and P =
1.2×10−47) (Fig 2A and 2B). Lp-PLA2 mass and activity were positively correlated in Cauca-
sians (r = 0.92), Hispanics (r = 0.98) and Chinese-Americans (r = 0.44), but inversely corre-
lated in African-Americans (r = -0.40).
We examined the association of rs10846744 with Lp-PLA2 mass and activity in MESA par-
ticipants. Meta-analysis across race/ethnic groups revealed a significant association of
rs10846744 with Lp-PLA2 activity (P = 0.001), Lp-PLA2 mass (P = 0.04), (Table 2).
Association of rs10846744 with inflammatory biomarkers in MESA
We selected the inflammatory biomarkers and fatty acids based on their availability in the
MESA database as well as their well-characterized roles in CVD. Meta-analysis across race/eth-
nic groups revealed association between rs10846744 and DPA/EPA ratio in trans-ethnic meta-
analysis with a log10 Bayes factor = 1.52. No additional parameters under investigation dem-
onstrated statistically significant association in fixed effects meta-analysis based on our Bonfer-
roni threshold of α0.05/27 traits0.0019, nor in trans-ethnic meta-analysis based on our
threshold of log10 Bayes factor< 1.5. We observed nominal associations between rs10846744
Fig 2. Lp-PLA2 mass and activity levels stratified by race in MESA. (A). Lp-PLA2 mass was measured using the
PLACTM test (17). In Caucasians, Lp-PLA2 mass was 188.1 [164.8–213.5] ng/ml (median [IQR], N = 1968); African-
Americans, 162.2 [136.5–188.1], N = 1166; Hispanic, 175.8 [153.9–198.5], N = 1138; and Chinese-Americans, 163.8
[136.8–187.4], N = 643. (B). Lp-PLA2 activity was measured by a radiometric assay using tritium-labeled platelet
activating factor [3H]PAF as the substrate (17). In Caucasians, median Lp-PLA2 activity was 153.0 [129.1–179.1] nmol/
min/ml (median [IQR], N = 1981); African-Americans, 134.4 [112.8–158.3], N = 1208; Hispanic, 151.2 [127.2–172.8],
N = 1159; and Chinese-Americans, 154.7 [127.2–177.6], N = 645. Kruskal-Wallis rank sum test indicated that there
were significant overall differences in either Lp-PLA2 mass or activity across race/ethnic groups (P = 1.2×10−88 and
P = 3.1×10−49 respectively). Wilcoxon rank sum test indicated that in Caucasians and Hispanics Lp-PLA2 mass was
significantly higher than in African-Americans and Chinese-Americans (Bonferroni corrected P = 4.9×10−67 and
P = 1.4×10−46, respectively), while for Lp-PLA2 activity, Caucasians, Hispanics, and Chinese-Americans had
significantly higher levels than African-Americans (Bonferroni corrected P = 1.2×10−47,1.3×10−19, 4.7×10−48,
respectively).
https://doi.org/10.1371/journal.pone.0204352.g002
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and homocysteine (P = 0.03), LDL particle number (P = 0.01), DHA (P = 0.01), DPA
(P = 0.04), and DHA/EPA (P = 0.008) (Table 2).
Mediation analysis of inflammatory and/or fatty acids in the association of
rs10846744 with cIMT and incident CVD in MESA
Based on the results of main effect association (Table 2), Lp-PLA2 activity and DHA/EPA ratio
were carried forward for mediation analysis. Using the bias-corrected bootstrap method, a
meta-analysis resulted in Lp-PLA2 activity, but not DHA/EPA, as a mediator in the association
of rs10846744 with cIMT (P = 0.00008) in a model adjusted for age, sex, study site, and PCs of
ancestry (Table 3). In a fully adjusted model, Lp-PLA2 activity was no longer a significant
mediator (Table 3).
Association of rs10846744 with CV events in STABILITY and SOLID-TIMI
52
We examined whether the Lp-PLA2 inhibitor darapladib would modify the association of
rs10846744 with CVD events in the STABILITY and SOLID-TIMI 52 studies (Table 4). In
STABILITY, meta-analysis showed an association of rs10846744 with baseline Lp-PLA2 activ-
ity (P = 7.2x10-11). When all subjects were pooled (n = 13,522), we observed an association of
the rs10846744 SNP with major cardiovascular events (MCE: composite of coronary heart dis-
ease death, MI, or urgent coronary revascularization for myocardial ischemia) (P = 0.04). We
did not observe a significant association of rs10846744 with major adverse cardiovascular
events (MACE) that was defined as CV death, MI, or stroke. We did not observe an interaction
effect between Lp-PLA2 activity or darapladib assignment and rs10846744 on CVD outcomes.
In SOLID-TIMI 52, we did observe significant associations of rs10846744 with baseline Lp-
PLA2 activity (all subjects pooled P = 1.18x10-4, meta-analysis P = 5.68x10-2). We did not
observe significant associations between rs10846744 and CV outcomes (MCE or MACE), and
neither were there any interactions between rs10846744 and Lp-PLA2 activity or darapladib
assignment.
Discussion
Our previous findings of a significant association of rs10846744 with CVD events in MESA
were consistent with findings in CARDIoGRAMplusC4D and STABILITY. Nonetheless, we
did not observe a significant association of rs10846744 with cIMT in CHARGE or CARe.
These discrepancies do not argue against the influence of this enhancer region on CV pheno-
types but for the urgent need to thoroughly evaluate the effect of linkage disequilibrium struc-
ture and gene-environment influences on CVD outcomes across different race/ethnic groups.
The rationale for examining the association of Lp-PLA2 mass and activity in the association
of rs10846744 with SCA and incident CVD was based on the fact that in MESA traditional risk
factors, including cholesterol levels, did not attenuate this significant association. In MESA
participants, meta-analysis revealed a large positive effect size and significant association of
Lp-PLA2 mass and activity with rs10846744. Based on race/ethnic stratification, we found that
the large effect size and significance between rs10846744 and Lp-PLA2 mass and activity was
observed in Hispanics. In Chinese-Americans we observed significance in the association of
rs10846744 with Lp-PLA2 activity, while in Caucasians we observed borderline significance
with Lp-PLA2 mass. Katan et al. [24] also examined race/ethnic differences in the association
of Lp-PLA2 mass and activity with stroke in participants of the Northern Manhattan Stroke
Study (NOMAS), with the majority of participants classified as Hispanics and female. They
Lp-PLA2, SCARB1 and CVD
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Table 3. Mediation analysis of inflammatory biomarkers and fatty acids in the association of rs10846744 with cIMT in MESA: Basic and fully adjusted models.
BASIC MODEL
Mediation variable Coefficient of rs10846744 Coefficient of rs10846744 Difference in coefficients Bias-Corrected Bootstrap




0.01104 0.01066 -0.00038 (-0.00183, 0.00011) 0.12
DPA/EPA
(n = 2217)




0.01400 0.01363 -0.00037 (-0.00338, 0.00247) 0.81
DPA/EPA
(n = 1464)




0.01922 0.01715 -0.00207 (-0.00482, -0.00050) 0.01
DPA/EPA
(n = 1237)




0.01574 0.01476 -0.00099 (-0.00421, 0.00038) 0.15
DPA/EPA
(n = 693)
0.01516 0.01489 -0.00027 (-0.00242, 0.00080) 0.46




Lp-PLA2 activity -0.00120 0.0003 7.5e-05 3.7 / 0.37
DPA/EPA -0.00010 0.0002 0.65 0.0 / 0.90
FULLY ADJUSTED MODEL
Variable Coefficient of rs10846744 Coefficient of rs10846744 Difference in coefficients Bias-Corrected Bootstrap




0.00949 0.00968 0.00019 (-0.00030, 0.00143) 0.32
DPA/EPA
(n = 2179)




0.0112 0.01111 -0.00009 (-0.00131, 0.00039) 0.50
DPA/EPA
(n = 1439)




0.01612 0.01545 -0.00067 (-0.00251, 0.00011) 0.11
DPA/EPA
(n = 1029)




0.01466 0.01486 0.00021 (-0.00122, 0.00212) 0.63
DPA/EPA
(n = 679)
0.01666 0.01675 0.00009 (-0.00117, 0.00184) 0.71
(Continued)
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observed significant association of Lp-PLA2 mass with large artery atherosclerotic stroke in
non-Hispanic Whites but not in African-Americans or Hispanics; these investigators did not
stratify results based on the rs10846744 SNP, which might offer an explanation for the differ-
ences in our study results.
PhospholipaseA2 is a phospholipase that can be secreted into the circulation (secretory Lp-
PLA2) or becomes lipoprotein associated (Lp-PLA2), with the latter mostly bound to LDL [25].
It was not too surprising that we identified a strong main effect of LDL particle numbers in the
association with rs10846744, and this significant association was only observed in Hispanics.
We did not observe significant main effects of HDL or its subfractions. Interestingly, of the
other parameters we examined, fatty acids were found to have significant main effects in asso-
ciation with rs10846744, although beta effects were small and at times in opposing directions.
Mediation analysis was performed to determine if Lp-PLA2 activity was a causal factor in
the association of rs10846744 with SCA. With the use of the bias-corrected bootstrap statistical
analysis, and a meta-analysis using a model adjusting for age, sex, study site, and PCs of ances-
try, we found that Lp-PLA2 activity was a significant mediator; however, in a fully adjusted
model, Lp-PLA2 activity was not a significant mediator. This result suggests that one or a com-
bination of the covariates in the fully adjusted model influences the mediation effect of Lp-
PLA2 activity in the association of rs10846744 with SCA. Interestingly, Holmes et al. has
addressed a research hypothesis similar to ours using Mendelian randomization studies to
examine the role of secretory PLA2 (sPLA2) isoenzymes in CHD [26,27] and has not identified
evidence for a causal role of these sPLA2 isoenzymes in CHD.
There has been a longstanding interest in the role of Lp-PLA2 mass and/or activity as a
causal factor in atherosclerosis based on its biological role in lipid oxidation and epidemiologi-
cal studies showing significant associations of Lp-PLA2 mass and/or activity with CAD [28–
30]. However, recent clinical trials with darapladib failed to show benefit on secondary preven-
tion of major coronary events [6,7]. In both STABILITY and SOLID, when stratified by the
rs10846744 genotype, we observed significant association of this SNP with Lp-PLA2 activity
(Lp-PLA2 mass was not ascertained in STABILTY or SOLID-TIMI 52). In STABILITY, we
observed a significant association of rs10846744 in survival analyses for MCE, but this associa-
tion was not modified by darapladib. That we observed an association of rs10846744 with
major cardiovascular events in STABILITY but not in SOLID-TIMI 52 might be due to the
higher prevalence of MI at baseline in STABILITY subjects as compared with SOLID-TIMI 52
participants. In addition, SOLID-TIMI 52 was a study of subjects with acute MI and the
Table 3. (Continued)




Lp-PLA2 activity -0.00001 0.0003 0.85 27.6 / 0.25
DPA/EPA -0.00010 0.0002 0.71 0.0 / 0.48
Basic model: Regression models were adjusted for age, sex, study site, and PCs of ancestry; Unlike model 2, model 1 did not include the mediation variable. DPA/EPA
was square root transformed. Genetic association shown for rs10846744 effect allele C (vs. reference allele G). For meta-analysis results, Heterogeneity I-squared and
Heterogeneity P-values from Cochran’s Q test are reported as implemented in METAL [21].
Fully adjusted model: Regression models were fully adjusted for age, sex, BMI, diabetes, creatinine, LDL, HDL, Lipid medication, hypertension, ever smoke (yes/no),
current smoke (yes/no), education, study site, and PCs of ancestry; Unlike model 2, model 1 did not include the mediation variable. DPA/EPA was square root
transformed. Genetic association shown for rs10846744 effect allele C (vs. reference allele G). For meta-analysis results, Heterogeneity I-squared and Heterogeneity P-
values from Cochran’s Q test are reported as implemented in METAL [21].
https://doi.org/10.1371/journal.pone.0204352.t003
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samples used for Lp-PLA2 activity were obtained, on average, at 14 days of hospitalization for
the MI event. These factors might also explain the differences in the association of rs10846744
with major coronary events between STABILITY and SOLID-TIMI 52.
In summary, we provide strong evidence for the association of rs10846744, which resides
within an enhancer region, with Lp-PLA2 activity and evidence from a number of large genetic
studies for association with CVD events. It has been shown that traditional CV risk factors do
not explain the association of rs10846744 and Lp-PLA2 with CV events. Mediation analysis
revealed that Lp-PLA2 activity was a significant mediator in the association of rs10846744 with
cIMT but only in a basic adjusted model. The fully adjusted model suggests that other factor(s)
remain to be identified in this inflammatory pathway. In agreement with Polfus et al. [31], it
Table 4. Association of rs10846744 with CV events in STABILITY and SOLID-TIMI 52 studies. In STABILITY, multivariable regression models included adjustment
for age, sex, region, BMI, hyperlipidemia, statin use, baseline LDL, baseline HDL, eGFR, smoking, diabetes, prior MI, principal components (PCs) of ancestry and random-
ized treatment arm. In SOLID-TIMI 52, multivariable regression models included adjustment for age, sex, region, BMI, hyperlipidemia, statin use, baseline LDL, baseline
HDL, eGFR, smoking, diabetes, prior MI, index diagnosis (STEMI vs not), days from qualifying event, PCs of ancestry and randomized treatment arm. Genetic associa-
tions are shown for rs10846744 effect allele C (vs. reference allele G).
STABILITY SOLID-TIMI 52
SCARB1 rs10846744 effects on LpPLA2 activity at baseline SCARB1 rs10846744 effects on LpPLA2 activity at baseline
Group MAF N Beta SE P-value Group MAF N Beta SE P-value
Caucasian 0.17 9448 4.15 0.67 5.52E-
10
Caucasian 0.16 7503 3.305 0.76 1.51E-
05
African-American 0.53 254 4.78 4.12 2.47E-
01
African-American 0.59 185 5.823 4.44 1.91E-
01
Asian 0.64 1257 3.18 2.06 1.22E-
01
Asian 0.62 408 -2.661 3.51 4.49E-
01
Other 0.25 1637 2.1 1.63 1.96E-
01








0.21 9399 2.581 0.67 1.18E-
04
Meta-analysis 12596 3.82 0.59 7.22E-
11
Meta-analysis 9399 2.209 1.16 5.68E-
02
SCARB1 rs10846744 survival analysis for MCE SCARB1 rs10846744 survival analysis for MCE
Group MAF N (events) Beta SE P-value Group MAF N (events) Beta SE P-value
Caucasian 0.17 9889(945) 0.0926 0.06 1.30E-
02
Caucasian 0.16 8136(1137) -0.017 0.06 7.70E-
01
African-American 0.53 265(38) -0.051 0.27 8.50E-
01
African-American 0.59 208(52) 0.1072 0.24 6.60E-
01
Asian 0.64 1641(101) 0.0894 0.15 5.60E-
01
Asian 0.62 424(35) 0.1801 0.29 5.30E-
01
Other 0.25 1727(180) 0.1906 0.13 1.30E-
01














Darapladib treatment as a modifier of rs10846744 effects in survival analysis of
MCE
Darapladib treatment as a modifier of rs10846744 effects in survival analysis of
MCE
Group Regression Term N (events) Beta SE P-value Group Regression Term N (events) Beta SE P-value
All subjects
pooled
SNP main effect 13522
(1264)
0.0108 0.14 0.94 All subjects
pooled
SNP main effect 10189
(1451)
-0.112 0.14 0.43









Treatment x SNP 13522
(1264)
0.0643 0.09 0.47 Treatment x SNP 10189
(1451)
0.0639 0.09 0.47
In both STABILITY and SOLID-TIMI 52, meta-analysis used random effects models across all race/ethnic groups.
https://doi.org/10.1371/journal.pone.0204352.t004
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appears that Lp-PLA2 activity is a biomarker for inflammation but it is not a primary mediator
for CVD events.
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